| Publication Year | Title | Author(s) |
| 2010 | Erratum: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study | Matteson, E. L. ; Han, J. ; Durez, P. ; Visvanathan, S. ; Xu, Z. ; Dasgupta, B. ; Kay, J. ; Hall, S. ; Hsia, E. C. ; Rahman, M. U. ; Wagner, C. ; Nash, P. |
| 2008 | Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study | Xu, Z. ; Kay, J. ; Dasgupta, B. ; Hall, S. ; Rahman, M. U. ; Hsia, E. C. ; Wagner, C. ; Han, J. ; Matteson, E. L. ; Visvanathan, S. ; Nash, P. ; Durez, P. |
| 2009 | Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis | Moreland, L. W. ; Churchill, M. ; Fleischmann, R. M. ; Emery, P. ; Doyle, M. K. ; Strusberg, I. ; Park, W. ; Xu, W. ; Amante, Eric ; Rahman, M. U. ; Hsia, E. C. ; Pons-Estel, B. A. ; Visvanathan, S. ; Durez, P. ; Nash, P. |
| 2008 | Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study | Park, W. ; Strusberg, I. ; Amante, Eric ; Xu, W. ; Rahman, M. U. ; Hsia, E. C. ; Pons-Estel, B. ; Churchill, M. ; Moreland, L. W. ; Emery, P. ; Fleischmann, R. M. ; Durez, P. ; Nasi, P. |
